Efficacy and Safety of Dual-Effect Myopia Control Lenses for Slowing Myopia Progression: A Single-Center, Randomized, Controlled, Noninferiority Trial
This study aims to evaluate the efficacy and safety of dual-effect myopia control spectacle lenses in slowing myopia progression compared with Nikon MyoEase 2.0 lenses in children aged 8-13 years.
This is a single-center, randomized, open-label, parallel-group, noninferiority clinical trial. A total of 194 children with myopia will be randomly assigned in a 1:1 ratio to wear either dual-effect myopia control spectacle lenses or Nikon MyoEase 2.0 lenses for 12 months.
The primary outcome is the change in cycloplegic objective spherical equivalent refraction from baseline to 12 months. Secondary outcomes include changes in refractive error, ocular biometric parameters, visual acuity, binocular visual function, and visual questionnaire scores. Safety will also be assessed throughout the study.
Studieoversikt
Status
Forhold
Intervensjon / Behandling
Studietype
Registrering (Antatt)
Fase
- Ikke aktuelt
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- Aged 8-13 years, regardless of sex, with written consent from both the participant and their legal guardian.
- Cycloplegic objective spherical equivalent refraction between -4.75 D and -0.75 D (inclusive) in both eyes, astigmatism ≥-1.50 D, and an absolute interocular difference in spherical equivalent refraction ≤1.00 D.
- Best-corrected visual acuity ≥1.0 in both eyes.
- Intraocular pressure within the normal range (10-21 mmHg) in both eyes.
- Voluntary participation in the study with signed informed consent.
Exclusion Criteria:
- History of ocular trauma or intraocular surgery.
- Clinically abnormal slit-lamp examination findings.
- Fundus examination grade ≥2.
- Other ocular diseases, including uveitis or other ocular inflammation, glaucoma, cataract, fundus disease, ocular tumors, ocular trauma, manifest strabismus, or any ocular condition affecting visual function.
- Systemic diseases associated with immunodeficiency or conditions considered by the investigator unsuitable for spectacle wear, such as diabetes, Down syndrome, rheumatoid arthritis, or psychiatric disorders.
- Participation in a drug clinical trial within the previous 3 months or a medical device clinical trial within the previous month.
- Meeting the inclusion criteria in only one eye.
- Inability to attend regular ophthalmic examinations.
- Participation in any myopia control clinical trial within the previous 3 months, or previous or current use of rigid contact lenses (including associated care products), multifocal contact lenses, progressive addition lenses or other specially designed myopia control spectacle lenses, or atropine.
- Deemed ineligible by the investigator.
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Enkelt
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Eksperimentell: Dual-Effect Myopia Control Lenses
Participants in this group will wear dual-effect myopia control spectacle lenses for 12 months, with a recommended daily wearing time of at least 12 hours. |
Dual-effect myopia control spectacle lenses manufactured by Jiangsu Kangmeida Optical Co., Ltd. Participants will be advised to wear the spectacles for at least 12 hours per day for 12 months. |
|
Aktiv komparator: Nikon Kongyoudian 2.0 Lenses
Participants in this group will wear Nikon Kongyoudian 2.0 spectacle lenses for 12 months, following the same wearing instructions as the experimental group. |
Nikon Kongyoudian 2.0 spectacle lenses manufactured by Nikon Optical Co., Ltd. The lenses will be used in the same manner as the investigational lenses for 12 months. |
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Change in Cycloplegic Spherical Equivalent Refraction at 12 Months
Tidsramme: Baseline and 12 months (±30 days)
|
Change in spherical equivalent refraction (SER) from baseline to 12 months, measured by objective autorefraction under cycloplegia. SER is calculated as sphere power plus half the cylinder power, expressed in diopters (D). |
Baseline and 12 months (±30 days)
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Change in Axial Length
Tidsramme: Baseline, 6 months (±30 days), and 12 months (±30 days)
|
Change in axial length from baseline, measured before cycloplegia using optical biometry. |
Baseline, 6 months (±30 days), and 12 months (±30 days)
|
|
Change in Cycloplegic Spherical Equivalent Refraction at 6 Months
Tidsramme: Baseline and 6 months (±30 days)
|
Change in spherical equivalent refraction (SER) from baseline to 6 months, measured by objective autorefraction under cycloplegia, expressed in diopters (D). |
Baseline and 6 months (±30 days)
|
|
Visual Acuity With Study Spectacles
Tidsramme: Baseline, 6 months (±30 days), and 12 months (±30 days)
|
Visual acuity measured while wearing the assigned study spectacles. |
Baseline, 6 months (±30 days), and 12 months (±30 days)
|
|
Change in Corneal Curvature
Tidsramme: Baseline, 6 months (±30 days), and 12 months (±30 days)
|
Change in corneal curvature from baseline, measured before cycloplegia using optical biometry. |
Baseline, 6 months (±30 days), and 12 months (±30 days)
|
|
Change in Anterior Chamber Depth
Tidsramme: Baseline, 6 months (±30 days), and 12 months (±30 days)
|
Change in anterior chamber depth from baseline, measured before cycloplegia using optical biometry. |
Baseline, 6 months (±30 days), and 12 months (±30 days)
|
|
Change in Lens Thickness
Tidsramme: Baseline, 6 months (±30 days), and 12 months (±30 days)
|
Change in crystalline lens thickness from baseline, measured before cycloplegia using optical biometry. |
Baseline, 6 months (±30 days), and 12 months (±30 days)
|
|
Change in Subjective Refraction
Tidsramme: Baseline, 6 months (±30 days), and 12 months (±30 days)
|
Change in subjective refraction from baseline, assessed before cycloplegia. |
Baseline, 6 months (±30 days), and 12 months (±30 days)
|
|
Best-Corrected Visual Acuity
Tidsramme: 6 months (±30 days) and 12 months (±30 days)
|
Best-corrected visual acuity assessed using an ETDRS logMAR E chart. |
6 months (±30 days) and 12 months (±30 days)
|
|
Change in Binocular Visual Function
Tidsramme: Baseline, 6 months (±30 days), and 12 months (±30 days)
|
Change in binocular visual function from baseline, assessed at follow-up visits. |
Baseline, 6 months (±30 days), and 12 months (±30 days)
|
|
Visual Questionnaire Score
Tidsramme: 6 months (±30 days) and 12 months (±30 days)
|
Visual assessment using the Chinese version of the PRER2 questionnaire. |
6 months (±30 days) and 12 months (±30 days)
|
Andre resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Incidence of Adverse Events and Serious Adverse Events
Tidsramme: Throughout the 12-month study period
|
Occurrence of symptoms, signs, complications, adverse events, and serious adverse events related to the study products or procedures. |
Throughout the 12-month study period
|
|
Intraocular Pressure
Tidsramme: 6 months (±30 days), and 12 months (±30 days)
|
Intraocular pressure measured using non-contact tonometry, expressed in mmHg. |
6 months (±30 days), and 12 months (±30 days)
|
|
Fundus Examination Grade
Tidsramme: 6 months (±30 days), and 12 months (±30 days)
|
Fundus findings assessed and graded according to the study protocol. |
6 months (±30 days), and 12 months (±30 days)
|
|
Spectacle Frame Position Assessment
Tidsramme: Baseline, 6 months (±30 days), and 12 months (±30 days)
|
Assessment of spectacle frame positioning and lens condition according to the study protocol. |
Baseline, 6 months (±30 days), and 12 months (±30 days)
|
Samarbeidspartnere og etterforskere
Samarbeidspartnere
Studierekorddatoer
Studer hoveddatoer
Studiestart (Antatt)
Primær fullføring (Antatt)
Studiet fullført (Antatt)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- 2026KYPJ157
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
IPD-planbeskrivelse
Individual participant data will not be shared with external researchers.
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .